Illumina Escapes Market Doldrums with 9 Percent Stock-Price Gain | GenomeWeb
As stocks across the US market suffered a second week of declines, Illumina managed to post a 9 percent gain in its stock price over the trading week ended Tuesday following strong Q2 results last week (see BioCommerce Week 7/25/2007).
Illumina led the eight shares that gained value during the tracking period, though none of the others eclipsed 5 percent growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.